The binding of the S component (LukS-PV) from the bicomponent staphylococca
l Panton-Valentine leucocidin to human polymorphonuclear neutrophils (PMNs)
and monocytes was determined using flow cytometry and a single-cysteine su
bstitution mutant of LukS-PV, The mutant was engineered by replacing a glyc
ine at position 10 with a cysteine and was labeled with a fluorescein moiet
y, The biological activity of the mutant was identical to that of the nativ
e protein. It has been shown that LukS-PV has a high affinity for PMNs (K-d
= 0.07 +/- 0.02 nM, n = 5) and monocytes (K-d = 0.020 +/- 0.003 nM, n = 3)
with maximal binding capacities of 197,000 and 80,000 LukS-PV molecules pe
r cell, respectively. The nonspecifically bound molecules of LukS-PV do not
form pores in the presence of the F component (LukF-PV) of leucocidin, Luk
S-PV and HlgC share the same receptor on PMNs, but the S components of othe
r staphylococcal leukotoxins, HlgA, LukE, and LukM, do not compete with Luk
S-PV for its receptor. Extracellular Ca2+ at physiological concentrations (
1 to 2 nM) has only a slight influence on the LukS-PV binding, in contrast
to its complete inhibition by Zn2+, The down-regulation by phorbol 12-myris
tate 13-acetate (PMA) of the binding of LukS-PV was blocked by staurosporin
e, suggesting that the regulatory effect of PMA depends on protein kinase C
activation, The labeled mutant form of LukS-PV has proved very useful for
detailed binding studies of circulating white cells by how cytometry, LukS-
PV possesses a high specific affinity for a unique receptor on PMNs and mon
ocytes.